Literature DB >> 15266552

Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study.

Estefanía Núñez1, Cristina Benito, M Ruth Pazos, Antonio Barbachano, Otto Fajardo, Sara González, Rosa M Tolón, Julián Romero.   

Abstract

Two types of cannabinoid receptors have been characterized so far, CB1 and CB2. While CB1 receptors are present both in the CNS and in the periphery, CB2 receptors showed an almost exclusive distribution within the immune system. We now report that CB2 receptors are present in a specific microglial cell type of the human cerebellum. Thus, we have performed immunohistochemical analysis of tissue sections of white matter areas of the human cerebellum and detected the presence of CB2 receptors in perivascular microglial cells. These findings match with the well-known immunomodulatory role of CB2 receptors and open new perspectives on the possible role that these receptors may play in pathophysiological events.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15266552     DOI: 10.1002/syn.20050

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  116 in total

Review 1.  Potential Therapeutical Contributions of the Endocannabinoid System towards Aging and Alzheimer's Disease.

Authors:  Amandine E Bonnet; Yannick Marchalant
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

Review 2.  Endocannabinoids in cerebrovascular regulation.

Authors:  Zoltán Benyó; Éva Ruisanchez; Miriam Leszl-Ishiguro; Péter Sándor; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-01-29       Impact factor: 4.733

3.  A glial endogenous cannabinoid system is upregulated in the brains of macaques with simian immunodeficiency virus-induced encephalitis.

Authors:  Cristina Benito; Woong-Ki Kim; Wong-Ki Kim; Iván Chavarría; Ceceila J Hillard; Ken Mackie; Rosa M Tolón; Kenneth Williams; Ken Williams; Julián Romero
Journal:  J Neurosci       Date:  2005-03-09       Impact factor: 6.167

4.  Cannabinoid receptors CB1 and CB2 form functional heteromers in brain.

Authors:  Lucía Callén; Estefanía Moreno; Pedro Barroso-Chinea; David Moreno-Delgado; Antoni Cortés; Josefa Mallol; Vicent Casadó; José Luis Lanciego; Rafael Franco; Carmen Lluis; Enric I Canela; Peter J McCormick
Journal:  J Biol Chem       Date:  2012-04-24       Impact factor: 5.157

5.  Unique effects of compounds active at both cannabinoid and serotonin receptors during stroke.

Authors:  Ming Zhang; Anu Mahadevan; Mukkanti Amere; Hongbo Li; Doina Ganea; Ronald F Tuma
Journal:  Transl Stroke Res       Date:  2012-07-26       Impact factor: 6.829

6.  Ligand-based virtual screening identifies a family of selective cannabinoid receptor 2 agonists.

Authors:  Matteo Gianella-Borradori; Ivy Christou; Carole J R Bataille; Rebecca L Cross; Graham M Wynne; David R Greaves; Angela J Russell
Journal:  Bioorg Med Chem       Date:  2014-11-08       Impact factor: 3.641

7.  Cannabinoids as anticancer therapeutic agents.

Authors:  Olga Kovalchuk; Igor Kovalchuk
Journal:  Cell Cycle       Date:  2020-04-05       Impact factor: 4.534

Review 8.  Meet Your Stress Management Professionals: The Endocannabinoids.

Authors:  Terri A deRoon-Cassini; Todd M Stollenwerk; Margaret Beatka; Cecilia J Hillard
Journal:  Trends Mol Med       Date:  2020-08-28       Impact factor: 11.951

9.  Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression.

Authors:  Emmanuel S Onaivi; Hiroki Ishiguro; Jian-Ping Gong; Sejal Patel; Paul A Meozzi; Lester Myers; Alex Perchuk; Zoila Mora; Patricia A Tagliaferro; Eileen Gardner; Alicia Brusco; B Emmanuel Akinshola; Qing-Rong Liu; Sanika S Chirwa; Bruce Hope; Javier Lujilde; Toshiya Inada; Shinya Iwasaki; David Macharia; Lindsey Teasenfitz; Tadao Arinami; George R Uhl
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

Review 10.  Alzheimer's disease; taking the edge off with cannabinoids?

Authors:  V A Campbell; A Gowran
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.